Company profile
NEXGEL, Inc.
NASDAQ: NXGL · Healthcare · Medical - Instruments & Supplies
#616 of 1,417 Healthcare companies by revenue72nd-percentile growth
EA Score
51DFH 51DQ 45GM 73SS 29
v0.1 · 65/100 weight · provisional
↑ 3-yr revenue growth, revenue growth (YoY) · ↓ listing tenure, Piotroski F
Methodology →Revenue TTM
$11.3M
Rev growth YoY (TTM)
+10.1%
Net income (FY)
-$3.0M
Employees
19
as of 2026-09-21
Market cap
$2.2M
as of 2026-09-21
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$11.4M$11.4M2025
Net income-$3.0M-$3.0M2025
Operating income-$3.4M-$3.4M2025
Total assets$10.5M$10.5M2025
Liabilities$5.6M$5.6M2025
Equity$4.5M$4.5M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY23
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2024
By product
Contract Manufacturing89%
Other Incomes11%
By geography
Not disclosed.
The read
What is NEXGEL, Inc.’s revenue?
NEXGEL, Inc. booked $11.4M in FY2025 revenue, growing 31% year over year — faster than most Healthcare companies we track, at a -26.3% net margin.
Peers · Healthcare
BIMI International Medical Inc.——Cardiff Lexington Corporation50DJaguar Health, Inc.38DJun An Kang Group Inc.——Caribou Biosciences, Inc.43DBellRock Brands Inc.——Neighbors
Bucks →Key facts
CEOBrian J. Kieser
SectorHealthcare
IndustryMedical - Instruments & Supplies
HeadquartersLanghorne, PA
ExchangeNASDAQ: NXGL
Employees19
IPO date2021-12-22
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.